Anivive Lifesciences strives to develop 'valley fever' prevention vaccine
Anivive Lifesciences' Chief Commerical Officer Chad Todd, DVM, discussed the future of Anivive Lifesciences including the development of a new vaccine.
In an interview from our Fetch dvm360® Kansas City Conference, Chad Todd, DVM, chief commercial officer at Anivive Lifesciences, shared insight on a new vaccine the company is working toward for the prevention of coccidioidomycosis, also referred to as “valley fever.”
"We are in the process of developing drugs not only in the oncology space, but we are also working on the development of a valley fever vaccine," Todd told dvm360® staff. "Valley fever is a condition that both people and pets are affected by and we do not have any preventions right now. It's very unfortunate because there are about 30 million dogs that are exposed to this pathogen."
He then explained that a person or canine diagnosed with this condition will likely endure lifelong therapy of antifungal treatments. Anivive strives to bring these unmet medical needs to the forefront by developing a preventative vaccine for valley fever.
Watch the full interview below for more information on Anvive Lifesciences and its mission.